BlueRock Therapeutics, LLC

BlueRock Therapeutics is a clinical-stage biotechnology company focused on developing innovative cell therapies for degenerative diseases, including therapies for Parkinson's disease and photoreceptor diseases. Founded in 2016 and based in Cambridge, US, BlueRock Therapeutics specializes in cellular medicine aimed at treating degenerative diseases. The company was acquired by Bayer AG in August 2019 for up to USD 600 mn, with an upfront payment of USD 240 mn and additional payments tied to development milestones. The company has conducted 2 deals to date, with the most recent deal completed on August 8, 2019.

Emile Nuwaysir and Seth Ettenberg are the current CEOs of the firm. BlueRock Therapeutics LP is a clinical-stage biotechnology company focused on developing advanced cell therapies for treating degenerative diseases. Their primary investigational therapies include OpCT-001, targeting primary photoreceptor diseases, and bemdaneprocel for Parkinson's disease. These therapies leverage cellular medicine to replace damaged cells, enhancing patient outcomes.

BlueRock serves a diverse clientele, including healthcare providers and pharmaceutical companies, and is actively conducting clinical trials in North America and Europe to advance these therapies. BlueRock Therapeutics generates revenue through collaborations with major pharmaceutical companies and research organizations, allowing for co-development of therapies and shared proceeds from successful commercialization. Revenue strategy centers on B2B partnerships, facilitating clinical trial participation and access to investigational therapies, with flagship products like OpCT-001 and bemdaneprocel at the forefront. Following Bayer AG's acquisition of BlueRock Therapeutics in August 2019, the company plans to utilize the recent funding to further develop its innovative therapies and expand its presence in both North American and European markets.

The acquisition, which is anticipated to close in Q3 2019, includes performance-based incentives that could amount to an additional USD 360 mn, contingent on clinical milestones, supporting BlueRock's strategy to introduce new products and enhance its operational capabilities.